Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
| Autor: | David J. Pinato, Francesco Facchinetti, Alessio Cortellini, Jose Carlos Benitez, Joao Victor Machado Alessi, Karla A. Lee, Paola Cravero, I. Sullivan, T. Gorria, A. Barba, F. Aboubakar Nana, Mark M. Awad, N. Hussain, Delphine Hoton, James Clark, Anita Bolina, L. Mezquita, Deepti Venkatraman, Margarita Majem, F.G. Dall'Olio, Diego Ottaviani, A. Piedra, Victor Vaz, Benjamin Besse, Giuseppe Lamberti, Biagio Ricciuti |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms predictive factors medicine.drug_class medicine.medical_treatment Immune checkpoint inhibitors First line Antibiotics Pembrolizumab chemotherapy antibiotics immune checkpoint inhibitors Carcinoma Non-Small-Cell Lung Internal medicine medicine Humans Lung cancer Chemo immunotherapy Chemotherapy business.industry Hematology medicine.disease Anti-Bacterial Agents Treatment Outcome non-small-cell lung cancer Immunotherapy Non small cell pembrolizumab business |
| Zdroj: | ANNALS OF ONCOLOGY r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 0923-7534 |
| Popis: | Background: Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut dysbiosis. Whether ATB also affects outcomes to chemo-immunotherapy combinations is still unknown. Patients and methods: In this international multicentre study, we evaluated the association between pATB, concurrent ATB (cATB) and overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in patients with non-small-cell lung cancer (NSCLC) treated with first-line chemo-immunotherapy at eight referral institutions. Results: Among 302 patients with stage IV NSCLC, 216 (71.5%) and 61 (20.2%) patients were former and current smokers, respectively. Programmed death-ligand 1 tumour expression in assessable patients (274, 90.7%) was >= 50% in 76 (25.2%), 1%-49% in 84 (27.9%) and = 7 versus |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|